JP2008500320A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500320A5
JP2008500320A5 JP2007514117A JP2007514117A JP2008500320A5 JP 2008500320 A5 JP2008500320 A5 JP 2008500320A5 JP 2007514117 A JP2007514117 A JP 2007514117A JP 2007514117 A JP2007514117 A JP 2007514117A JP 2008500320 A5 JP2008500320 A5 JP 2008500320A5
Authority
JP
Japan
Prior art keywords
pyrimidin
thiazol
methyl
phenyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007514117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500320A (ja
JP5026259B2 (ja
Filing date
Publication date
Priority claimed from GBGB0411791.7A external-priority patent/GB0411791D0/en
Application filed filed Critical
Publication of JP2008500320A publication Critical patent/JP2008500320A/ja
Publication of JP2008500320A5 publication Critical patent/JP2008500320A5/ja
Application granted granted Critical
Publication of JP5026259B2 publication Critical patent/JP5026259B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007514117A 2004-05-26 2005-05-26 増殖性障害の治療に有用な2−置換−4−ヘテロアリール−ピリミジン Expired - Fee Related JP5026259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0411791.7A GB0411791D0 (en) 2004-05-26 2004-05-26 Compounds
GB0411791.7 2004-05-26
PCT/GB2005/002134 WO2005116025A2 (en) 2004-05-26 2005-05-26 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders

Publications (3)

Publication Number Publication Date
JP2008500320A JP2008500320A (ja) 2008-01-10
JP2008500320A5 true JP2008500320A5 (OSRAM) 2008-06-19
JP5026259B2 JP5026259B2 (ja) 2012-09-12

Family

ID=32671118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007514117A Expired - Fee Related JP5026259B2 (ja) 2004-05-26 2005-05-26 増殖性障害の治療に有用な2−置換−4−ヘテロアリール−ピリミジン

Country Status (11)

Country Link
US (1) US20090137572A1 (OSRAM)
EP (1) EP1756098A2 (OSRAM)
JP (1) JP5026259B2 (OSRAM)
CN (1) CN1989138A (OSRAM)
AU (1) AU2005247682A1 (OSRAM)
BR (1) BRPI0511616A (OSRAM)
CA (1) CA2566051A1 (OSRAM)
GB (1) GB0411791D0 (OSRAM)
IL (1) IL179508A0 (OSRAM)
MX (1) MXPA06013632A (OSRAM)
WO (1) WO2005116025A2 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
CN101083996A (zh) * 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
US7968538B2 (en) * 2005-01-25 2011-06-28 Galenea Corp. Substituted arylamine compounds and methods of treatment
CN101203500B (zh) * 2005-01-25 2013-08-21 格利尼公司 取代的芳胺化合物和它们作为5-ht6调节剂的用途
BRPI0706621A2 (pt) 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
WO2007132220A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
WO2009011880A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
US20110190280A1 (en) * 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
KR20100090772A (ko) * 2007-10-12 2010-08-17 인게니움 파르마코이티칼스 게엠베하 단백질 키나제 억제제
WO2009076140A1 (en) * 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
JP5711537B2 (ja) 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ピリミジン−2−アミン化合物およびjakキナーゼの阻害剤としてのその使用
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 縮合複素環式化合物およびそれらの使用
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2011059610A1 (en) * 2009-11-10 2011-05-19 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
RU2606497C2 (ru) * 2011-02-24 2017-01-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
JP6106685B2 (ja) * 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド C−jun−n−末端キナーゼ(jnk)の阻害剤
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015154038A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の阻害剤
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10479785B2 (en) * 2015-08-04 2019-11-19 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CN111757881B (zh) * 2018-01-15 2024-05-07 澳升医药公司 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN111039941B (zh) * 2018-10-12 2023-03-21 上海医药集团股份有限公司 一种含氮杂环化合物、其制备方法及应用
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2024259116A1 (en) * 2023-06-14 2024-12-19 Prothena Biosciences Limited 5-(cinnolin-6-yl)thiazole compounds for treating neurological disorders
CN116903592B (zh) * 2023-07-13 2025-08-01 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
KR960704855A (ko) * 1993-10-12 1996-10-09 돈 엠. 커. 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof)
GB9519275D0 (en) * 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP4205165B2 (ja) * 1996-05-08 2009-01-07 サイクラセル リミテッド Cdk4活性の阻害のための方法と手段
US6703395B2 (en) * 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
CA2231005A1 (en) * 1998-03-04 1999-09-04 Libor Havlicek Cyclin dependent kinase inhibitor
KR100581199B1 (ko) * 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AU4262901A (en) * 2000-03-29 2001-10-08 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
ES2274035T3 (es) * 2001-06-01 2007-05-16 Vertex Pharmaceuticals Incorporated Compuestos de tiazol utiles como inhibidores de proteina quinasas.
US20040181066A1 (en) * 2001-08-01 2004-09-16 Fraley Mark E. Tyrosine kinase inhibitors
MXPA04002914A (es) * 2001-09-28 2005-06-20 Cyclacel Ltd N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
JP2006524688A (ja) * 2003-03-25 2006-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
WO2005012298A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
AU2004261484A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP5164380B2 (ja) * 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−4−イル−3,4−チオン化合物及び治療におけるその使用
JPWO2005113550A1 (ja) * 2004-05-20 2008-03-27 三菱ウェルファーマ株式会社 アミノピリミジン誘導体及びその医薬としての用途

Similar Documents

Publication Publication Date Title
JP2008500320A5 (OSRAM)
JP2007520540A5 (OSRAM)
RU2451673C2 (ru) ПРОИЗВОДНЫЕ ПИРИДИНА И ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
JP2007509117A5 (OSRAM)
US20090137572A1 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
RU2008117170A (ru) Пиримидинамидные соединения как ингибиторы pgds
RU2454415C2 (ru) Производное индола
JP2008524248A5 (OSRAM)
RU2426731C2 (ru) Производные арил-изоксазоло-4-ил-оксадиазола
DK2038265T3 (en) Inhibitors of human protein tyrosine phosphatase and methods of use
JP2007523142A5 (OSRAM)
JP2013517273A5 (OSRAM)
CN1926121B (zh) 噻唑衍生物及其应用
CA2590939A1 (en) Aminopyrimidine compounds and methods of use
US20040110810A1 (en) 2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases
JP2011526616A5 (OSRAM)
JP2010215644A5 (OSRAM)
JP2007500178A5 (OSRAM)
JP2015533157A5 (OSRAM)
RU2010115574A (ru) Замещенные амиды, фармацевтическая композиция на их основе, способ лечения заболевания, чувствительного к btk, способ повышения чувствительности раковых клеток к химиотерапии, способ уменьшения ошибок при приеме лекарства и улучшения соблюдения схемы лечения, способ ингибирования гидролиза атф, способ определения присутствия btk в образце и способ ингибирования активности в-клеток
JP2002332266A (ja) PPAR−γモジュレータ
JP2009542659A5 (OSRAM)
JP2008519850A5 (OSRAM)
JP2010540452A5 (OSRAM)
JP2003525872A5 (OSRAM)